KR20200054910A - 젬카빈, 이의 약학적으로 허용 가능한 염, 조성물 및 이의 사용 방법 - Google Patents
젬카빈, 이의 약학적으로 허용 가능한 염, 조성물 및 이의 사용 방법 Download PDFInfo
- Publication number
- KR20200054910A KR20200054910A KR1020197031929A KR20197031929A KR20200054910A KR 20200054910 A KR20200054910 A KR 20200054910A KR 1020197031929 A KR1020197031929 A KR 1020197031929A KR 20197031929 A KR20197031929 A KR 20197031929A KR 20200054910 A KR20200054910 A KR 20200054910A
- Authority
- KR
- South Korea
- Prior art keywords
- gemcarbine
- subject
- pharmaceutically acceptable
- less
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/08—Saturated compounds containing ether groups, groups, groups, or groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/47—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/305—Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762486728P | 2017-04-18 | 2017-04-18 | |
| US201762486822P | 2017-04-18 | 2017-04-18 | |
| US62/486,822 | 2017-04-18 | ||
| US62/486,728 | 2017-04-18 | ||
| US201762569358P | 2017-10-06 | 2017-10-06 | |
| US62/569,358 | 2017-10-06 | ||
| US201762584576P | 2017-11-10 | 2017-11-10 | |
| US62/584,576 | 2017-11-10 | ||
| PCT/US2018/028113 WO2018195163A1 (en) | 2017-04-18 | 2018-04-18 | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200054910A true KR20200054910A (ko) | 2020-05-20 |
Family
ID=63791570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197031929A Withdrawn KR20200054910A (ko) | 2017-04-18 | 2018-04-18 | 젬카빈, 이의 약학적으로 허용 가능한 염, 조성물 및 이의 사용 방법 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20180297929A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3612171A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2020516622A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200054910A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110996928A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3059073A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL269884B2 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201902471A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018195163A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3218349A2 (en) | 2014-11-14 | 2017-09-20 | Gemphire Therapeutics Inc. | Processes and intermediates for preparing , -dicarboxylic acid-terminated dialkane ethers |
| EP3612171A4 (en) | 2017-04-18 | 2020-10-21 | Gemphire Therapeutics Inc. | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME |
| JP2022505033A (ja) * | 2018-10-18 | 2022-01-14 | ジェムフィアー セラピューティクス インコーポレイテッド | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 |
| US20240226049A1 (en) * | 2023-01-09 | 2024-07-11 | Esperion Therapeutics, Inc. | Methods of treatment using bempedoic acid |
| WO2024151311A1 (en) * | 2023-01-09 | 2024-07-18 | Esperion Therapeutics, Inc. | Methods of treatment using bempedoic acid |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2033909A (en) | 1934-12-19 | 1936-03-17 | Niacet Chemicals Corp | Manufacture of calcium levulinate |
| CA1197242A (en) * | 1983-03-02 | 1985-11-26 | Jean A. Gauthier | Pyrimido¬1,2-a|pyrrolo¬2,1-c|¬1, 4|benzodiazepine-3-carboxylic acid derivatives |
| US4691034A (en) | 1986-04-14 | 1987-09-01 | Texaco, Inc. | Purification of propylene oxide by treatment with calcium hydroxide in glycerol or sugar water |
| US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| EP1017390B1 (en) | 1997-07-31 | 2007-04-18 | Kos Life Sciences, Inc. | Coated tablet comprising nicotinic acid or a compound metabolized to nicotinic acid in an extended release form, and a coating containing an hmg-coa reductase inhibitor in an immediate release form |
| US6861555B2 (en) * | 2000-01-25 | 2005-03-01 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| US6459003B1 (en) | 1999-04-01 | 2002-10-01 | Esperion Therapeutics, Inc. | Ether compounds |
| NZ519550A (en) | 2000-01-25 | 2003-11-28 | Warner Lambert Co | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| US6500457B1 (en) | 2000-08-14 | 2002-12-31 | Peirce Management, Llc | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent |
| CN100376570C (zh) | 2000-10-13 | 2008-03-26 | 希拉生物化学股份有限公司 | 改善胞间传输的二氧戊环类似物 |
| HUP0400381A2 (hu) | 2001-06-29 | 2004-09-28 | Warner-Lambert Company Llc | [R-(R*,R*)]-2-(4fluorfenil)-béta, delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)karbonil]-1H-pirrol-1-heptánsav 2:1 arányú kalciumsójának (atorvasztatin) kristályos formái |
| US20040192771A1 (en) | 2001-10-11 | 2004-09-30 | Dasseux Jean-Louis Henri | Ether compounds and compositions for cholesterol management and related uses |
| DE10211289A1 (de) | 2002-03-14 | 2003-09-25 | Basf Ag | Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität |
| WO2003088962A1 (en) | 2002-04-16 | 2003-10-30 | Merck & Co., Inc. | Combination therapy using a ppar alpha/gamma agonist |
| AU2003227691B2 (en) | 2002-05-03 | 2008-05-15 | Hexal Ag | Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor |
| JP2006501238A (ja) | 2002-08-22 | 2006-01-12 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 骨関節炎を治療する方法 |
| WO2004045596A1 (en) | 2002-11-15 | 2004-06-03 | Warner-Lambert Company Llc | Method of lowering crp and reducing systemic inflammation |
| ES2645930T3 (es) | 2003-01-03 | 2017-12-11 | Supernus Pharmaceuticals, Inc. | Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas |
| WO2005002557A1 (en) | 2003-07-03 | 2005-01-13 | Warner-Lambert Company Llc | Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof |
| US20050026979A1 (en) | 2003-07-31 | 2005-02-03 | Maha Ghazzi | Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
| US7345190B2 (en) | 2003-11-12 | 2008-03-18 | Ssv Therapeutics, Inc. | Carnitine conjugates as dual prodrugs and uses thereof |
| WO2006054308A2 (en) | 2004-11-22 | 2006-05-26 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
| FR2891459B1 (fr) | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| CA2628666A1 (en) | 2005-11-21 | 2007-05-24 | Teva Pharmaceutical Industries Ltd. | Atorvastatin formulation |
| CN104825397A (zh) | 2006-04-03 | 2015-08-12 | 伊萨·奥迪迪 | 含有机溶胶涂层的受控释放递送物件 |
| US7777071B2 (en) | 2006-08-11 | 2010-08-17 | Ssv Therapeutics, Inc. | Production of carnitine conjugate intermediates |
| US20080241240A1 (en) | 2006-08-24 | 2008-10-02 | Hanall Pharmaceutical Co., Ltd. | Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors |
| WO2008022932A2 (en) | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
| FI20080353A0 (fi) | 2008-05-09 | 2008-05-09 | Atacama Labs Oy | Prosessi erittäin korkean lääkepitoisuuden tabletin valmistamiseksi |
| US9486446B2 (en) | 2006-12-28 | 2016-11-08 | Takeda Pharmaceutical Company Limited | Orally disintegrating solid preparation |
| CZ300047B6 (cs) | 2007-03-02 | 2009-01-21 | Zentiva, A. S. | Farmaceutická kompozice s obsahem úcinné látky atorvastatinu |
| WO2008124505A2 (en) | 2007-04-05 | 2008-10-16 | Ironwood Pharmaceuticals,Inc. | Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US20090036414A1 (en) | 2007-08-02 | 2009-02-05 | Mutual Pharmaceutical Company, Inc. | Mesalamine Formulations |
| WO2009024889A2 (en) | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
| WO2009048938A1 (en) | 2007-10-08 | 2009-04-16 | Keen Ingredients, Inc. | Quinoa grain processing and products |
| BRPI0822026B8 (pt) | 2008-01-10 | 2021-05-25 | Evonik Roehm Gmbh | preparação farmacêutica ou nutracêutica, comprimido, gelatina ou cápsula de hpmc, e uso de uma ou uma mistura de uma pluralidade de polímeros ou copolímeros |
| US20090226515A1 (en) | 2008-03-04 | 2009-09-10 | Pharma Pass Ii Llc | Statin compositions |
| FR2928925B1 (fr) | 2008-03-19 | 2011-01-07 | Centre Nat Rech Scient | Complexes de bore ou d'aluminium, et leurs utilisations. |
| EP2285352A2 (en) | 2008-05-13 | 2011-02-23 | Dr. Reddy's Laboratories Ltd. | Atorvastatin compositions |
| RU2010151944A (ru) | 2008-05-20 | 2012-06-27 | Серенис Терапьютикс С.А. (Fr) | Ниацин и нспвс для комбинированной терапии |
| RU2404767C1 (ru) | 2009-08-11 | 2010-11-27 | Закрытое Акционерное Общество "БИОКОМ" | Твердая лекарственная форма, обладающая гиполипидемической и гипохолестеринемической активностью, и способ ее получения |
| AU2011270719B2 (en) | 2010-06-24 | 2015-09-24 | Arisaph Pharmaceuticals, Inc. | Niacin mimetics, and methods of use thereof |
| TR201005325A2 (tr) | 2010-06-30 | 2012-01-23 | Bi̇lgi̇ç Mahmut | Atorvastatin ve aspirin içeren farmasötik formülasyonlar |
| PL2592081T3 (pl) | 2010-07-06 | 2017-07-31 | Ono Pharmaceutical Co., Ltd. | Pochodna tetrahydrokarboliny |
| TW201304823A (zh) | 2010-12-27 | 2013-02-01 | Takeda Pharmaceutical | 口腔內崩壞錠 |
| ES2608177T3 (es) | 2010-12-27 | 2017-04-06 | Gemphire Therapeutics Inc. | Gemcabeno y derivados para el tratamiento de la pancreatitis |
| UA112539C2 (uk) | 2011-03-03 | 2016-09-26 | Новартіс Аг | Спосіб одержання похідних 2-карбоксамідциклоаміносечовини |
| CA2835293C (en) * | 2011-06-08 | 2020-08-18 | Sti Pharma, Llc | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration |
| RU2491070C2 (ru) | 2011-10-11 | 2013-08-27 | Общество с ограниченной ответственностью "Фармамед" | Фармацевтическая композиция для профилактики и лечения сердечно-сосудистых заболеваний |
| EP2787986B1 (en) | 2011-12-08 | 2017-10-18 | Syndromex Ltd. | Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof |
| EP2604256B1 (en) | 2011-12-14 | 2016-04-13 | Hexal AG | Multi layer coatings |
| JP6295205B2 (ja) * | 2012-01-06 | 2018-03-14 | ジェムファイア セラピューティクス インクGemphire Therapeutics Inc. | 心血管疾患のリスクを低減する方法 |
| CN104127391B (zh) | 2014-08-05 | 2016-08-24 | 李宝齐 | 一种含有阿托伐他汀钙的固体药物组合物 |
| EP3218349A2 (en) * | 2014-11-14 | 2017-09-20 | Gemphire Therapeutics Inc. | Processes and intermediates for preparing , -dicarboxylic acid-terminated dialkane ethers |
| MX2018005096A (es) * | 2015-11-06 | 2018-08-15 | Gemphire Therapeutics Inc | Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular. |
| CN105434391A (zh) | 2016-01-18 | 2016-03-30 | 上海蓝心医药科技有限公司 | 阿托伐他汀钙肠溶片及其制备方法和应用 |
| EP3612171A4 (en) | 2017-04-18 | 2020-10-21 | Gemphire Therapeutics Inc. | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME |
| WO2018209257A1 (en) | 2017-05-11 | 2018-11-15 | Gemphire Therapeutics Inc. | Gemcabene compositions and methods of use thereof |
-
2018
- 2018-04-18 EP EP18788278.2A patent/EP3612171A4/en not_active Withdrawn
- 2018-04-18 WO PCT/US2018/028113 patent/WO2018195163A1/en not_active Ceased
- 2018-04-18 TW TW107113223A patent/TW201902471A/zh unknown
- 2018-04-18 CA CA3059073A patent/CA3059073A1/en active Pending
- 2018-04-18 IL IL269884A patent/IL269884B2/en unknown
- 2018-04-18 KR KR1020197031929A patent/KR20200054910A/ko not_active Withdrawn
- 2018-04-18 US US15/956,172 patent/US20180297929A1/en not_active Abandoned
- 2018-04-18 JP JP2019555180A patent/JP2020516622A/ja active Pending
- 2018-04-18 CN CN201880040555.5A patent/CN110996928A/zh active Pending
-
2019
- 2019-05-03 US US16/402,853 patent/US20200148617A1/en not_active Abandoned
-
2022
- 2022-01-24 US US17/583,081 patent/US12503422B2/en active Active
-
2023
- 2023-01-26 JP JP2023010250A patent/JP2023057082A/ja active Pending
-
2025
- 2025-11-21 US US19/397,103 patent/US20260209157A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023057082A (ja) | 2023-04-20 |
| IL269884B2 (en) | 2023-09-01 |
| JP2020516622A (ja) | 2020-06-11 |
| CN110996928A (zh) | 2020-04-10 |
| TW201902471A (zh) | 2019-01-16 |
| US20200148617A1 (en) | 2020-05-14 |
| US20180297929A1 (en) | 2018-10-18 |
| IL269884A (cg-RX-API-DMAC7.html) | 2019-11-28 |
| IL269884B1 (en) | 2023-05-01 |
| EP3612171A1 (en) | 2020-02-26 |
| EP3612171A4 (en) | 2020-10-21 |
| US20260209157A1 (en) | 2026-07-23 |
| US20220332672A1 (en) | 2022-10-20 |
| US12503422B2 (en) | 2025-12-23 |
| CA3059073A1 (en) | 2018-10-25 |
| WO2018195163A1 (en) | 2018-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12503422B2 (en) | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | |
| KR102011641B1 (ko) | 치환된 퀴나졸리논을 위한 경구 즉시 방출 제형 | |
| TWI268778B (en) | Benzamide derivative-containing pharmaceutical formulation having improved solubility and oral absorptivity | |
| WO2001095912A1 (fr) | Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph | |
| JP2021522247A (ja) | 肝疾患における好中球エラスターゼ阻害薬の使用 | |
| JPH02268178A (ja) | 3―ホルミルアミノ―7―メチルスルホニルアミノ―6―フェノキシ―4h―1―ベンゾピラン―4―オンまたはその塩を含有する抗炎症製剤 | |
| KR20210093900A (ko) | 젬카빈, 이의 약학적으로 허용가능한 염, 이의 조성물 및 이의 사용 방법 | |
| US20190008779A1 (en) | Gemcabene compositions and methods of use thereof | |
| JP2025527686A (ja) | オビセトラピブ及びエゼチミブ併用治療及び固定用量医薬組成物 | |
| WO2025168614A1 (en) | Pharmaceutical compositions comprising azd0780 | |
| WO2007075009A1 (en) | Complex formulation comprising amlodipine camsylate and simvastatin and method for preparation thereof | |
| EP2395837A1 (en) | Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia | |
| HK40027589A (en) | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | |
| EP2154958A1 (en) | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies | |
| AU2009327374A1 (en) | Treatment of major adverse cardiac events and acute coronary syndrome using secretory phospholipase A2 (sPLA2) inhibitor or sPLA2 inhibitor combination therapies | |
| WO2025069226A1 (ja) | ペマフィブラートを含有する医薬 | |
| US20190070167A1 (en) | Pitavastatin containing preparation and method for producing same | |
| WO2011052499A1 (ja) | 貯蔵安定性が改善された医薬組成物 | |
| WO2011137390A1 (en) | Treatment of major adverse cardiac events and acute coronary syndrome in diabetic patients using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies | |
| KR20100109840A (ko) | 분비성 포스포리파제 a2 (spla2) 억제제를 사용한 심혈관 질환 및 이상지혈증의 치료 및 spla2 억제제 조합 요법 | |
| Radiosensitizer | Azelnidipine Antihypertensive |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20191028 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210407 Comment text: Request for Examination of Application |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20230921 |
|
| WITB | Written withdrawal of application |